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SUMMARY
Open spina bifida is one ofthe most common neural tube defects and one of
the most serious that originates early in pregnancy. There is no cure. One way to
address this problem is through early detection and prevention.
The objective ofthis research is to identify risk cutoffvalues in maternal
serum alpha-fetoprotein (MSAFP) screening that maximize the economic benefits to
society. The MSAFP is a blood test where a risk cutoffvalue is selected. An
individual testing at or above this value is considered at increased risk ofhaving a
fetus with spina bifida. A net benefit approach is used to identify several risk cutoff
values at different incidence rates. The net benefit approach consists of several steps.
First, this approach uses a formula that assumed benefits and costs to prenatal
screening for spina bifida, with the difference being the net benefit. There are three
rates that influence this formula: incidence rate, detection rate and false positive rate.
Next, this method uses simulated data ofdetection and false positive rates that
correspond to different risk cutoffvalues. The results from the simulation are
inserted into the net benefit formula, which produces the net benefit at each risk
cutoffvalue and incidence rate. The net benefit approach is the tool used to evaluate
if current screening is being optimized. This approach does not attempt to pass
judgment on the life ofan individual. This is one approach to address prenatal
screening for spina bifida.
The results show that there are different optimal risk cutoffvalues, depending
on the incidence rate selected. If clinics use accurate incidence rates, rates that
directly reflect the population they are screening, screening can be optimized. The
optimal risk cutoffvalue(s) for that specific incidence rate can be used. This benefits
the patient, the medical community and society.
The net benefit approach is a useful tool for screening for spina bifida. The
sensitivities ofthe individual must continue to be taken into consideration.
Background
Birth defects are the leading cause of infant mortality in the United States.
Among birth defects, neural tube defects are some ofthe most serious malformations
that originate early in pregnancy. Open spina bifida is one ofthe most common
neural tube defects. This disorder occurs when the spinal cord does not develop
properly and the skin cannot form and cover the spinal cord and vertebrae.
Individuals with spina bifida require extensive medical treatment throughout their
lives. Surgical intervention, therapy, special education and institutional care are
common. Disabilities can include weakness or paralysis ofthe legs, urinary and fecal
incontinence, hydrocephaly and mental retardation (Wald and Cuckle, 1984).
Spina bifida affects not only the individual, but families and society as well.
Medical care costs are burdensome to the family. In addition, time spent traveling to
and from appointments and the psychological and emotional effects are intangible
costs borne by the families that deal with this every day. The burden to society can
be calculated through the loss ofpotemial earnings for individuals with spina bifida.
The national incidence for spina bifida (reported by the CDC in 1995) is 4.6 per
10,000 live births or I per 2,174 live births. There are over four million births in the
United States every year. There were 4,064,948 births in 2000 (NVSS, 2001). This
incidence implies approximately 1,870 cases ofspina bifida. The CDC also reports
that the average lifetime cost estimated for a person with spina bifida is $532,000.
The cost to society is approximately $1 billion per year.
There is no cure for spina bifida. However, one action that can be taken is
prevention. In this case, prevention can be achieved through the utilization of
diagnostic and screening tests. Diagnostic tests can identify cases of spina bifida with
near perfect accuracy. Once a case of spina bifida is identified, action may be taken
to terminate the pregnancy. Prenatal screening tests are used to identify the risk of
potential birth defects and give families time to prepare and make decisions that may
affect the outcome ofpregnancy. However, diagnostic and screening tests involve
risks and specific considerations that must be taken into account, as will be discussed
in this paper.
Amniocentesis is the diagnostic test used to positively identify a fetus with
open spina bifida. This test is a medical procedure performed during pregnancy to
help determine the health of a fetus. It involves the withdrawal ofa small amount of
amniotic fluid that surrounds the fetus in the mother’s uterus. With this procedure,
spina bifida is 1 ofmore than 150 serious birth disorders that can be diagnosed. Prior
to the 1980s, it was the main tool used in screening for neural tube defects. However,
with improvements in the accuracy ofultrasound (one type of screening test), the
screening protocol has changed. Amniocentesis is now primarily used ifthe
screening tests show positive results and the pregnant woman agrees to accept certain
risks associated with this procedure.
The most significant risk is that amniocentesis may cause the affected or
unaffected fetus to spontaneously abort. Ifthe amniocentesis were administered to
every pregnant woman in the United States, based on the rate of spontaneous abortion
with this procedure, this would result in the loss ofapproximately 20,325 fetuses
(4,064,948 births x 0.005% (Beazoglou, et al., 1998)). This would also result in the
detection of 1,870 cases ofspina bifida (4,064,948 births x 1/2174 (incidence rate)).
In addition to posing a risk to the fetus, amniocentesis is the most costly (compared to
screening tests) to administer. The average cost is $1200 (Vintzileos, et al., 1998).
The cost ofadministering this diagnostic test to every pregnant woman would be
approximately $4.9 billion per year (4,064,948 births x $1200). Based on these two
factors, risk of fetal loss and cost, it is clear that amniocentesis cannot be
administered to every pregnant woman. Therefore, it is important to optimize the use
of screening to avoid unnecessary fetal losses and to reduce economic costs.
The utilization of screening tests is a preliminary method for spina bifida.
Maternal serarn alpha-fetoprotein (MSAFP) and routine ultrasonography are the
specific tests used to detect cases of open spina bifida. The MSAFP is a blood test
administered between the 16th and 18th weeks ofpregnancy, the optimum gestational
age to conduct MSAFP screening as determined by the First U.K. Collaborative
Study (Knight and Palomaki, 1992). A cutoffvalue is selected for this test, with
above-average levels indicating an increased risk of spina bifida.
The ultrasound is an important supplement to MSAFP screening. Although
historically the ultrasound test was not very accurate, the detection rate has increased
to more than 80% (Vintzileos, et al., 1998) over the past two decades. Ultrasound
helps reduce the proportion ofunaffected pregnancies regarded as having elevated
MSAFP levels. It does this by revising the estimate of gestational age in women who
appear to have elevated levels due to the underestimation ofthe gestational age. It is
important to note a distinction with regard to ultrasound screening. Genetic
ultrasound screening, the most precise method ofultrasound screening, has higher
detection rates than routine ultrasounds. However, this screening procedure is not
available in every area in the United States.
While neither the MSAFP nor the ultrasound screening tests pose risks to the
fetus, there are differences between the two methods in both accuracy and cost. The
ultrasound has been shown to have a high detection rate, yet is more expensive than
the MSAFP screening test ($300 vs. $20; Vintzileos, et al., 1998 and Beazoglou, et
al., 1998, respectively). The accuracy ofthe MSAFP screening test depends on the
risk cutoffvalue selected. The risk cutoffvalue detemnes how accurate the test will
be (detection rate and false positive rate). As in the case ofthe amniocemesis, it is
not economically feasible to administer the ultrasound to every pregnant woman.
The cost ofadministering ultrasound screening for every pregnant woman would
amount to approximately $1.22 billion per year (4,064,948 births x $300 (Vintzileos,
et al., 1998)). Therefore, MSAFP screening, the least expensive test in this process,
is the recommended first step in screening for spina bifida.
Screening tests do not provide a clear-cut distinction between affected and
unaffected fetuses. This is an extremely important concern because them is an overlap
between the MSAFP levels found in affected and unaffected pregnancies. As stated
earlier, in order to detect cases ofopen spina bifida through MSAFP screening, one
risk cutoffvalue is selected. Any results that are at or above that risk cutoffvalue are
considered to be positive. That is, those fetuses are identified as more likely to be
affected. Similarly, any results below the selected risk cutoffvalue are considered
negative, and less likely to be affected. There is no specific MSAFP cutoff value that
completely separates the unaffected from the affected pregnancies.
As with any non-diagnostic screening test, there is a range oftrade-offs
associated with the risk cutoffvalue chosen. The risk cutoffvalue selected inherently
determines and influences the detection rate and false positive rate. Appendix 1
demonstrates the sensitivity ofchoosing various risk cutoffvalues. The cutoffvalue
that is chosen varies across clinical labs. In the United States, most labs use 2.0 or
2.5 MOM (multiples ofthe median) as the cmoffvalue (Knight and Palomaki, 1992).
The MSAFP screening test is not 100% accurate and affected cases may not
be detected. Similarly, unaffected cases may be incorrectly identified as affected.
Figures 1 and 2 in Appendix 1 each illustrate two distributions: unaffected and
affected. There are four areas in each distribution influenced by the risk cutoffvalue:
true negative, false negative, true positive and false positive. True negative
represems the pregnancies that have unaffected fetuses and are classified as
unaffected. False negative represents the pregnancies that have affected fetuses, but
that are erroneously classified as unaffected. True positive represents the pregnancies
that have affected fetuses and are classified as affected. False positive represents the
pregnancies that have unaffected fetuses, but that are erroneously classified as
affected. Figure 1 shows a selected risk cutoffvalue of2.0 MOM. The curve to the
left (U) represents the unaffected fetuses. The curve to the fight (A) represents the
affected fetuses. It is important to note that these two distributions are not to scale.
The curve to the left (U) represents the over 4 million births per year. The curve to
the right (A) represents the 1,870 cases ofspina bifida (based on the 1/2174 incidence
rate). The distribution for the unaffected cases that are erroneously classified as
positive for spina bifida is represented by all ofthe cases to the fight ofthat line.
Therefore, the area ABC represents cases that are considered affected, when in fact
they are unaffected. These represent the false positive cases. The distribution for
affected cases, at the same 2.0 MOM level, that are erroneously classified as
unaffected for spina bifida is represented by all ofthe cases to the left ofthat line.
Therefore, the area ABD represents cases that are considered unaffected, when in fact
they are affected. These represent the false negative cases.
Figure 2 can also be used to illustrate the proportional change in the four areas
if a higher risk cutoffvalue of 3.0 MOM is selected. Once again, the curve to the left
(U) represents the unaffected fetuses and the curve to the right (A) represents the
affected fetuses. When the 3.0 MOM value is selected as the risk cutoffvalue, all
cases to the right ofthat vertical line are considered affected. Similarly, all cases to
the left ofthe vertical line are considered unaffected. Therefore, the area ABC
represents cases that are considered affected, when in fact they are unaffected, the
false positive cases. Similarly, when the 3.0 MOM level is selected as the risk cutoff
value, all cases to the left ofthe vertical line are considered unaffected. Therefore,
the area ABD represents cases that are considered unaffected, when in fact they are
affected. These represent the false negative cases. A risk cutoffvalue of2.0 MOM
will result in a higher detection rate, but also a higher false positive rate. Many
pregnant women will be told their fetus is at risk for being bom with spina bifida,
when in fact the fetus may be unaffected. Conversely, a risk cutoffvalue of3.0
MOM will result in a lower detection rate and a lower false positive rate. Many
pregnant women will be told their fetus is not at risk for being bom with spina bifida,
when in fact the fetus is at risk. There is no doubt that selecting a risk cutoffvalue is
difficult because ofthe consequences of selecting higher or lower detection rotes.
As stated earlier, the risk cutoffvalue for detecting cases of spina bifida is not
consistent. It varies across areas in the United States and across countries. The ability
and method to compare clinical results among different sites was established in the
First U.K. Collaborative study. The study determined that the best method to
compare results from the various laboratories was to express all MSAFP
measurements as multiples ofthe median (MOM). As a result, the most common
cutoffvalues currently being used are 2.0 and 2.5 MOM (the cutoffpoint is defined
aseMSAFP concentration at or above which additional diagnostic procedures
would be implemented). At the 2.5 MOM value, this study showed that 79% of
pregnancies with spina bifida were associated with an MSAFP level at or above this
cutoffvalue (Appendix 2). The corresponding false positive rate was 3.3%. The
study also looked at 2.0 MOM, which identified 91% ofpregnancies with spina
bifida. However, it was also noted that this high sensitivity was at the expense ofa
greater number of screen-positive pregnancies not affected with spina bifida, a larger
percentage of false positive results. The false positive rate was 7.2%. At first glance,
this may seem low compared to the 91% of affected pregnancies that would test true
positive. However, using the current United States figure of4,064,948 million births
per year, this would translate into 263,409 (3,658,453 births x 7.2%) fetuses testing
positive for spina bifida, when in fact they are unaffected (assuming that 90% of
pregnant women would be screened).
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The U.K. Collaborative Study established the most efficient risk cutoffvalue
based on a specific level of false positive cases acceptable to the scientific
community. However, this evaluation was not conducted from the perspective of
society and disregarded the maximization ofnet economic benefits. In the current
environment of increasing medical costs and managed care cost containment issues,
resources clearly have alternative uses. The purpose ofthis evaluation is to determine
the best way of utilizing these resources.
EPIDEMIOLOGY
Three main types ofneural tube defects are anencephaly, spina bifida and
encephalocele. Anencephaly and spina bifida account for approximately 50% and
45%, respectively, of all neural tube defects. Encephalocele is rare, accounting for
the remaining 5%. "Anencephaly is fatal at, or within hours ofbirth, but the outcome
of spina bifida is variable" (Wald and Cuckle, 1984). In unaffected pregnancies, the
spine encloses and protects the spinal cord. Spina bifida occurs when the spinal cord
does not develop properly and the vertebrae and skin cannot form around it.
There are several types of spina bifida, each varying in severity. The most
familiar and most serious type is open spina bifida (also called meningomyelocele).
In such cases, the spinal cord does not close properly during the first month of
pregnancy, resulting in an open lesion. This type of spina bifida can be life
threatening during infancy and causes mild to severe disabilities in those who survive.
Often those affected are stillborn or die in infancy, while many ofthe survivors need
surgical intervention, remedial therapy, aids to mobility and special education, and
some need institutional care throughout their lives. As stated earlier, disabilities are
common in individuals affected with open spina bifida. "Even with the best surgical
intervention 25% to 60% (depending on age group being studied) remain wheel-chair
bound, between 6% and 40% are reported to have serious mental impairment, up to
85% are severely handicapped and 90% show urinary incominence" (Furhmarm and
Weitzel, 1992). Prenatal screening tests and ultrasound examinations during
pregnancy are used to detect open spina bifida in a fetus. However, there are cases
of spina bifida where the spinal cord does not close properly, but where a thick
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membrane covers the opening (also called closed spina bifida). These cases ofclosed
spina bifida cannot be detected by screening. Therefore, this paper will only be
evaluating those cases ofopen spina bifida.
The average life expectancy for people born with spina bifida has improved
over the years. Today, life expectancy is normal for most children born with this
condition. The prognosis is influenced by many factors, including medical stavas and
complications, independence in activities of daily living, and educational training and
opportunities.
OBJECTIVES
Cutoffvalues have been established to define pregnancies at high risk for
spina bifida without regard to optimization. This optimal value needs to be
established. Screening requires a trade-offbetween the detection rate and false
positive rate. The purpose ofthis paper is to find the optimal risk cutoffvalue from
the perspective of society. It needs to be stressed that this evaluation does not place a
value on an affected individual’s life. Affected and unaffected individuals differ only
with respect to the social costs associated with medical treatment and lost earnings.
Conducting a cost-benefit analysis will identify the optimal cutoffvalue and level of
net benefits to society. This paper will utilize a net benefit formula to illustrate the
various levels ofnet social benefits associated with spina bifida screening.
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METHODS
Evaluating the net benefit of prenatal screening for spina bifida will be
determined by using United States population and birth statistics and calculating the
net benefit from the perspective of society. The unit ofmeasurement for the net
benefit will be expressed as a dollar amount. The net benefit formula, originally
developed to maximize the net benefit in Down syndrome screening (Beazoglou, et
al., 1998), has been modified based on parameters specific to spina bifida. In order to
identify the optimal risk cutoffvalue, various pairs of detection and false positive
rates associated with alternative cutoffvalues will be applied to the net benefit
formula. The detection rate is defined as the rate oftrue positive cases. The unit of
measurement for the risk cutoffvalue will be expressed as a MOM. This formula will
identify the combination, and hence the risk cutoffvalue, that provides the maximum
net benefit per case to society. This approach includes a combination ofclinical and
economic variables ofprenatal screening for spina bifida. It is important to note that
assumptions were made for selected variables as a result ofa lack of existing data.
Uptake rates for MSAFP screening, routine ultrasound screening and amniocentesis
were assumed (90%, 70%, 70%, respectively) and based on uptake rates for prenatal
screening for Down syndrome. The net benefit for the MSAFP screening test is
defined as:
NB [I x D x U x F1 x S(F2 x (B-C1))] [C2+C3 x U(D x I/FP(1-I))]
NB
I
D
U
Net benefit per screened individual
Incidence rate
Detection rate ofMSAFP screening test
Uptake rate for amniocentesis (after positive screening test)
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F1
S
F2
B
C1
C2
C3
FP
Fetus survival rate following amniocentesis
Termination rate following positive amniocentesis
Fetus survival rate to birth
Benefits ofprenatal screening (cost savings from preventing birth of
affected child)
Cost of abortion
Cost ofMSAFP screening test
Cost ofamniocentesis
False positive rate ofMSAFP screening test
This formula is made up oftwo parts: benefits and costs. The difference
between the two is the net benefit, measured in dollars. The first half ofthe formula
represents the benefit side:
[I x D x U x F1 x S(F2 x (B-C1))]
The benefits ofprenatal screening are defined as preventing the birth ofa baby with
spina bifida. The incidence rate (I) is defined by the affected and unaffected
pregnancies at the time of screening. The detection rate (D) defines the sensitivity of
the screening test. The incidence and detection rates are variable in this formula. As
previously memioned, the uptake rate (U) used is based on assumptions. The fetal
survival rate (F1) defines the rate of fetuses that survive to birth. The fetal
termination rate (S) addresses the rate ofabortions after a positive amniocentesis. The
fetus survival rate to birth (F2) defines the rate that fetuses make it through the term
ofpregnancy and factors in human intervention and spontaneous abortion (unrelated
to amniocentesis). The benefit ofprenatal screening (B) defines the lifetime cost for
an individual with spina bifida. This cost includes lifetime direct medical,
developmental and special education costs, as well as lifetime lost wages and
productivity. The last component ofthe benefit side ofthe formula is the cost of
16
having an abortion (C 1). This represents the fetuses that do not make it to term due to
human intervention. The second halfofthe formula represents the cost side:
[C2+C3 x U(D x I+FP(1-I))]
The costs are defined as the direct costs per patient associated with prenatal
screening. The costs for MSAFP screening (C2) and amniocentesis (C3) are fixed at
$20 and $1200, respectively.
The following table shows the above variables with their associated costs and values.
I
D
U
F1
S
F2
B
C1
C2
C3
FP
1"500, 1"1000; 1"1500,1:2000, 1:2500,1"3000
Variable (according to model)
70% (this can vary and be adjusted as needed)
0.995% (Vintzileos, etal.,1998)
0.90% (assumption based on Beazoglou, et al., 1998)
.097 (Beazoglou, et al., 1998)
$532,000 (MMWR, 1995)
= $2000 (Vintzileos, et al., 1998)
$20 (Beazoglou, et a1.,1998)
$1200 (Vintzileos, et ai.,1998)
Variable (according to model)
The three components that drive this formula are the incidence rote, detection rate and
false positive rate and each one varies. In an effort to simplify this complicated
formula, the specified rates and costs in the above table can be calculated into
constant values. The resulting simplified formula is:
NB [322,226 x I x D] [20 + 840(D x I + FP (1-I))]
Once the incidence rate is selected, the corresponding false positive and detection
rates are inserted into the formula and multiplied by the corresponding constant
values. Another way to illustrate the steps in the formula is with a decision-making
tree that can be found in Appendix 3. This shows the progression of steps that a
pregnant woman takes with regard to prenatal screening.
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The CDC uses 1:2174 for the incidence ofspina bifida at birth in the United
States. This represents the risk, unadjusted for maternal age, ofhaving a child with
spina bifida. Although the incidence rate for spina bifida screening is a main
determinant ofcalculating the varying net benefits per individual, the incidence rate is
not uniform across clinics in this country. Therefore, the following incidence rates
will be included in the analysis: 1"500, 1" I000; 1" 1500,1:2000, 1:2500 and 1:3000.
Depending on which incidence rote is selected in each clinic, the maximum net
benefit will be determined in this evaluation. It is important to note that the incidence
of spina bifida at birth is being used in this evaluation. The tree incidence of spina
bifida occurring during pregnancy is higher. It is difficult to determine the tree
incidence during pregnancy because the rate of spontaneous abortion and human
intervention directly affects this.
Currently, there is not enough existing data to report on prenatal screening for
spina bifida. Some detection and false positive rates have been published (Wald, et
al., 1984; Wald, et al., 1992; Haddow and Palomaki, 1992). However, this analysis
requires more data than what is currently available. Therefore, this evaluation will
utilize a simulation model (Reynolds, et al., 1993) to execute the net benefit formula.
This model was developed into a computer program that is based on the statistical
software S-Plus (S-PLUS 4, 1997). This simulation program wilt give the estimated
risk ofa neural tube defect pregnancy at various detection and false positive rates, it
is important to note that the results ofthe simulation are similar to published data for
spina bifida screening. The model will generate risk cutoffvalues for 100,000
affected and 100,000 unaffected cases based on summary statistics (means and
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standard deviations). Wald and Cuckle published these parameters in 2000 (Wald and
Cuckle, 2000). Once the incidence rates are specified, the program will generate
pairs ofdetection and false positive rates, as well as the corresponding MOM levels
and risks. The final step after the simulation is to calculate the net benefit per case.
The formula is inserted into an Excel spreadsheet. The only variables in this formula
are the three rates that drive the formula: incidence rate, false positive rate and the
detection rate. Therefore, the three resulting rates from the simulation are entered
into the net benefit formula. The net benefit per case will be automatically calculated.
It has been mentioned in some ofthe literature that some clinics that provide
pregnant women access to genetic ultrasound screening (versus routine ultrasound
screening) do not typically recommend amniocentesis. The accuracy for detecting
cases ofopen spina bifida with the genetic ultrasound screening is more than 90%. In
order to address the protocol for these selected clinics, the formula will be slightly
modified:
NB [I x D x U x S(F2 x (B-C1))] [C2+C3 x U(D x I+FP(1-I))]
Changes to the original formula include the exclusion ofthe risk ofspontaneous
abortion (due to amniocentesis) and to the cost ofthe ultrasound after screening (C3)
is $300. The results will be evaluated and shown for both screening protocols in
Appendices 4, 5 and 6.
RESULTS
Several incidence rates were evaluated (1"500, 1"1000, 1"1200, 1"1500,1:2000,
1:2174, 1:2500 and 1:3000) in order to determine the net benefit per case for each
pairing ofdetection and false positive rates. For every incidence rate, the
corresponding MOM, risk and net benefit per case (based on amniocentesis or
ultrasound screening protocols) will be derived. Appendices 4, 5 and 6 show the
results for each incidence rate (assuming a 70%, 80% and 60% amniocentesis uptake
rate, respectively) after MSAFP screening.
Several key findings have emerged from this analysis. It appears that for a
number ofdifferent incidence rates and at different uptake rates, the optimal risk
cutoffvalue may not be unique. Appendix 7 shows a summary ofthe results at the
1/2174 incidence rate. Based on the simulation, using a rate of 1:360, which is
equivalent to 2.8 MOM, the following 69% detection rate and 1% false positive rate
are generated. These two values, along with the 1/2174 incidence rate, are inserted
into the net benefit formula. The net benefit per case is determined to be $64.
Appendix 7 shows that the maximum net benefit per case, at the 1/2174 incidence
rate, occurs at this risk rate (or MOM level). These results illustrate that as the
detection rate decreases, the false positive rate also decreases, while the net benefit
per case increases. This occurs only until the 2.8 MOM level. At that point, the net
benefit per case begins decreasing. At the 1/2174 incidence rate (assuming 70%
uptake rate), there is one optimal risk cutoffvalue. However, other incidence rates
show multiple optimal risk cutoffvalues.
19
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The results in Appendix 4 for the incidence rate 1/500 illustrate that the net
benefit per case for amniocentesis is $457. This optimal net benefit occurs at two
separate MOMs (2.0 and 2.1) and two different risk values (1/400 and 1/320).
Similarly, the ultrasound protocol for the same incidence and uptake rate shows that
there are two different optimal risk cutoffvalues and net benefit amounts. According
to the ultrasound protocol, the optimal risk cutoffvalues are at 1.4 and !.5 MOMs and
have a corresponding net benefit of$540. Overall, the results obtained at different
incidence and uptake rates show that in many cases, two or three risk cutoffvalues
yield the maximum net benefit. The results in Appendix 4, at each specified incidence
rate, show that there may be more than one MOM level that achieves the maximum
net benefit per case. For an incidence rate of 1/1000, the optimal net benefit per case
occurs at 2.3 and 2.4 MOM in the amniocentesis screening protocol. These two
levels show the maximum net benefit per case is $194. The corresponding risk
values are 1:430 and 1:350, respectively. These risk values are higher than those at
lowerMOM levels. If 2.0 MOM is used as the cutoffvalue, the net benefit per case
decreases to $184, and the risk decreases to 1:810. Ifthe ultrasound protocol is
utilized at this incidence rate of 1/1000, the maximum net benefit per case is $242 at
1.7 MOM.
Another key finding is that a lower incidence rate implies a higher optimal
MOM and lower net benefit. Appendix 8 shows a summary ofthe maximum net
benefits across selected incidence rates. As the incidence rate decreases, 1/1000 to
1/2000, the maximum net benefit per case also decreases. The optimal MOM rate, on
the other hand, increases. The incidence rate of 1/1000 (according to the
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amniocentesis screening protocol) shows the maximum net benefit per case at $194.
The maximum net benefit per case occurs at 2.3 and 2.4 MOMs. At the incidence
rate 1/2000, the maximum net benefit per case decreases to $74 and the MOM rate
increases and occurs at 2.6, 2.7 and 2.8. The risk cutoffvalue remains relatively
similar. At the 1/1000 incidence rate, the risk cutoffvalues at the maximum net
benefit ($194) are 1:350, 1:430. At the 1/2500 rate, the risk cutoffvalues at the
maximum net benefit ($52) are 2.8, 2.9, 3.0 MOMs (1:410, 1"350 and 1:290,
respectively). These risk cutoffvalues do not appear to vary greatly among the
maximum net benefits per case among incidence rates.
As the amniocentesis and ultrasound protocols slightly vary, the results also
vary. Across the selected incidence rates, the maximum net benefits per case are
consistently higher in the ultrasound protocol than the amniocentesis. The
corresponding MOM levels tend to be lower in the tfltrasound protocol as well. At the
1/1000 incidence rate (assuming 70% uptake rate), the maximum net benefit for the
amniocentesis protocol ($194) occurs at 2.3 and 2.4 MOMs. The ultrasound protocol
shows that, at this incidence rate, the maximum net benefit per case ($242) occurs at
1.7 MOM. Similarly, at the 1/2500 incidence rate, the maximum net benefit ($52) for
the amniocentesis protocol occurs at 2.8, 2.9 and 3.0 MOMs. The ultrasound
protocol, at this incidence rote, shows that the maximum net benefit per case ($73)
occurs at 2.0, 2.1 and 2.2 MOMs. This pattern is consistent across the different
incidence and uptake rates.
The results discussed in this section reflect the various incidence rates selected
and include assumptions ofuptake rates following MSAFP screening. Uptake rates
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and other componems ofthis net benefit formula can be modified to represent
individual clinics appropriately. One factor that appears to vary from the 60% to 80%
uptake rate is the maximum net benefit per case. It appears to be significantly higher
in the 80% uptake rate. Conversely, the 60% uptake rate illustrates the maximum net
benefit per case results are significantly lower.
DISCUSSION
Evaluating the standard 2.0 and 2.5 MOM cutoffvalues used in clinics across
the United States, the research shows that at specific incidence rates, these do not
consistently provide the maximum net benefit per case. At the 70% amniocentesis
uptake rate, selecting 2.0 MOM as the cutoffvalue provides the maximum net benefit
only at an incidence rate of 1/500 (according to the amniocentesis screening
protocol). Selecting 2.0 MOM as the cutoffvalue for the ultrasound screening
protocol finds the maximum net benefit to occur at the incidence rates of
1/1500,1/2000 and 1/2500.
At the 70% uptake rate, selecting 2.5 MOM as the cutoffvalue provides the
maximum net benefit only at incidence rates of 1/1200 and 1/1500 (according to the
amniocentesis screening protocol). Selecting 2.5 MOM as the cutoffvalue according
to the ultrasound screening protocol finds that the maximum net benefit never occurs
at any ofthe incidence rates examined.
If clinical protocol is based on adhering to the most recent incidence rate
published by the CDC of 1:2174, the maximum net benefit per case ($64) occurs at
2.8 MOM. The detection rate is 69%, the false positive rate is 1.9% and the risk
cutoff is 1:360. One important issue to note is the fact that clinical protocol may
compete with the economic results ofthis evaluation. Ultimately, the incidence rate
selected inherently determines the detection rate and false positive rate to use, based
on the maximum net benefit. Again, this evaluation shows that the maximum net
benefit is $64. However, clinical decision-making may determine that a 69%
detection rate is not acceptable. An 85% detection rate may be a more preferred or
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acceptable clinical protocol. If this were the case, this would result in a 12% false
positive rate, where the corresponding net benefit per case is $8. Clinical decision-
making is an important factor to weigh when discussing maximizing net benefits.
Though this evaluation is based on maximizing the net benefits to society, medical
decisions and protocols affect the individual patient.
It is important to note that this evaluation looks at the aggregate risk rather
than the individual risk. There are a number of factors that are not taken into
consideration that will be discussed later in this section (e.g. maternal weight, race
and ethnicity, etc.). Because ofthe variability of individuals, this approach is helpful
however individual factors must be taken into consideration.
There is a progression of steps in the screening process for spina bifida. The
pregnant mother is responsible for making a decision at each step in the process. For
each decision, there are specific outcomes. At each step in the screening process,
each individual patient has a choice to continue further screening. However,
decisions need to be made as to how far in the screening process each woman will
proceed to ensure that she is carrying an unaffected baby. At each step in the
process, there is constantly a risk of spontaneous abortion. Another factor that must
be kept in mind is that some screening may yield false negative results.
For MSAFP screening, the optimal net benefits are calculated at different
levels ofvarying pairs ofdetection and false positive rates. Stated earlier in this
paper is the notion that this evaluation has been conducted only from the perspective
of society. Therefore, all optimal net benefits are from this perspective. Ifthe goal is
to optimize the benefits ofMSAFP screening, methods have to be adjusted to ensure
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that the net benefits are maximized. In the United States, the most common risk cut-
offvalues for MSAFP screening are 2.0 and 2.5 MOM, respectively. However, the
policy of selecting these two values has not been with regard to optimizing the net
benefits of society. This analysis illustrates the importance of weighing the detection
and false positive rates in conjunction with the corresponding net benefit. The current
clinical policy results in selection ofrisk cutoffvalues that do not maximize net
benefits. In addition, in some cases the associated risks are high.
Clinical practice could be improved based on the findings ofthis evaluation.
Utilizing the optimal risk cutoffvalue could lower the number ofamniocenteses
performed, thereby reducing the number of fetuses lost by spontaneous abortion. If
the optimal value is not used, the number offalse negatives or false positives increase
(depending on risk cutoffvalue selected). Overall, clinicians and pregnant mothers
would benefit from using the optimal rate.
Other factors that affect the outcome and MSAFP screening include maternal
weight, multiple pregnancies, repeat MSAFP testing, folic acid and race. MSAFP
levels have been found to increase as maternal weight decreases (Knight and
Palomaki, 1992). The explanation behind this is that lighter women have less volume
ofblood; therefore the AFP levels are more concentrated when entering the matemal
circulation than in heavier women (Wald and Cuckle, 1982). The solution is to adjust
the MSAFP cutoffvalue for maternal weight. Ifno adjustments are made, lighter
women and fewer heavier women will test positive for open spina bifida. One study
that adjusted the cutoffvalue to the corresponding matemal weight noted a decrease
ha the false positive rate from 2.8% to 2.0% (Wald and Cuckle, 1982). There was not
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a significant change in the detection rate. It is also important to note that the percent
ofwomen this affects in the screening population is very small.
Multiple pregnancies are also an issue in MSAFP screening. MSAFP levels
tend to be higher in multiple pregnancies than in singleton pregnancies, in proportion
to the number offetuses (Knight and Palomaki, 1992). The problem is to determine
the most appropriate MSAFP cutoff rate. Knight and Palomaki offer a logical
suggestion: to select a cutoff for twins that would yield the same number of false
positive results in a singleton pregnancy. For example, if 2.0 MOM were selected as
the cutoff rate for singleton pregnancies, selecting 4.0 MOM for twin pregnancies
would be the solution. Although this would result in similar false positive rates, it is
likely that the detection rate would decrease. Therefore, this method would not be as
efficient. There is not much data available regarding MSAFP levels and multiple
pregnancies. There is even less information on multiple pregnancies where either one
or all ofthe fetuses are affected with open spina bifida. The U.K. Collaborative
Study reported only 8 cases ofmultiple pregnancies with affected fetuses (Wald and
Cuckle, 1984), In this study, 3.5 MOM was used as the cutoffrate for the cases of
multiple pregnancies. This resulted in a less than 50% detection rate. Another issue
raised in this situation is an ethical one: how can anyone justify terminating the
affected and unaffected twin fetuses? Though it may be unlikely that both fetuses are
found to be affected, this is still a controversial issue. Furhmann and Weitzel (1985)
determine that "there is no reliable way to derive cut-off values for twin pregnancies
from the distribution ofAFP values in singletons". The implication is that more
studies need to be conducted with twin pregnancies and MSAFP screening.
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Opinions differ about the value of repeating MSAFP testing. One opinion.is
that conducting repeat testing for those cases that test positive will reduce the false
positive rate, without affecting the detection rate. The idea is that the pregnancy will
be classified correctly after the second test (Knight and Palomaki, 1992). Wald and
Cuckle believe that "there is no practical value in carrying out a repeat MSAFP test
on either the same or a fresh sample taken up to one month later". The explanation
for this is that the fluctuations are so small that it does not provide much ofa benefit
relative to the additional cost.
Numerous studies have demonstrated that women who take a daily
multivitamin containing folic acid before becoming pregnant and in the early weeks
ofpregnancy have a lower risk ofhaving a baby with a neural robe defect, such as
spina bifida or anencephaly, than women who do not take multivitamins during this
period.
Race has been reported as also influencing the results ofMSAFP screening.
The prevalence ofopen neural tube defects differs among white, black and hispanic
women. The National Institutes ofHealth Collaborative and Perinatal Project
reported that t_he prevalence ofopen NTDs was significantly higher in white women
than in any other race (Phillips and Elias, 1992). According to Knight and Palomaki,
"black women have MSAFP values that average 10-15% higher than those ofwhite
women." The authors go on confirm that prevalence, however, is higher in white
women; "in addition to having higher MSAFP values, black women have only about
halfthe birth prevalence offetal open NTDs as white women".
CONCLUSIONS
In the United States, pregnant women have a choice in participating in
prenatal screening. Similarly, each woman has a choice in electing to undergo further
tests, such as ultrasound or amniocentesis. The decision to terminate or to continue a
pregnancy is also a choice, even in cases where the fetus tests positive for a specific
disorder. There are many ethical issues that are involved in discussions ofthis
nature, especially when the process may lead to termination ofan unaffected fetus.
This analysis is only meant to evaluate prenatal screening from a social and economic
perspective. Decisions regarding prenatal testing and outcomes are difficult to make.
There are no clear-cut boundaries for "fight" or "wrong" decisions. This evaluation
simply provides information about the maximum economic net benefit ofvarious
protocols. Screening policies should not be based only on an economic perspective,
but should also include those ofthe individual patient.
This paper has evaluated screening for spina bifida by using a net benefit
approach. The net benefit approach is a useful tool that addresses a serious problem.
Although there is no cure for this birth defect it can be detected and prevented. This
analysis uses simulated data, summary statistics and characteristics ofthe U.S.
population and some broad assumptions on the uptake rates for MSAFP screening,
ultrasound and amniocentesis. In addition, the paper excludes the effects of maternal
age, multiple pregnancies, the effect of folic acid and racial differences. The
incidence rate selected ultimately determines the detection and false positive rates.
These three components together determine the optimal risk cutoffvalue that
maximizes screening.
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RECOMMENDATIONS
The net benefit approach is a useful tool in addressing the issue of screening
for open spina bifida. This is an economic perspective and though it should not be
ignored, similarly it should not be the only component factored into the decision-
making process.
Prenatal screening policies differ across clinics and labs throughout the United
States. The research shows that at specific incidence rates, these do not consistently
provide the maximum net benefit per case and current screening policies are not
being optimized. Therefore, clinics and labs need to use better estimates of incidence
rates that reflect the characteristics ofthe population they are screening. This will
affect the welfare ofthe families and fetuses. For example, ifa clinic is using 1"1000
for the incidence rate and assuming a 70% uptake rate, there are two optimal risk
cutoffvalues that should be used: 2.3 and 2.4. For this specific incidence and uptake
rate, the net benefit per case is $194.
This research also points to a need for more rigorous studies to evaluate other
factors that affect screening that were mentioned in the paper, but not directly
included in the analysis. The net benefit method has shown that detection and false-
positive rates are directly influenced by the incidence rate selected.
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Distribution of Screening Values
Figure 1
b
2.0
Maternal Serum AFP Levels (MOM)
Figure 2
b
3.0
A
Maternal Serum AFP Levels (MOM)
U unaffected cases
Key:
A affected cases
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Risk Cut-offRate: percent > or
2.0 2.5 3.0 3.5 4.0
Affected 91% 79%
(sensitivity)
Unaffected 7.2% 3.3%
(false positive rate)
Table l(Detection and false positive rates from the First U.K. Collaborative Study at different risk
7O% 64% 45%
1.4% 0.6% 0.3%
cutoff rates)
Appendix 3
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Incidence..!/500 70% Uptake Rate
et Benefit Her Benefit
Detection Risk Per Case Per Case
Rate False Positive 1:/ MOM Amniocentesis Ultrasound
0.98388 0.49958 6300 1 193 512
0197669 01422’53 4500 111 253 523
_.0,96792 0.35612 3.200 1.2 303 532
0.95746 0.29914 2400 1.3 344 537
0.94592 0.24988 1800 1.4 378 540
0.9323 0.2078 1400 1.5 405 540
0.91756 0.17187 1000 1.6 425 538
0.90148 O. 14301 820 1.7 439 533
0.88461 O. 11906 640 1.8 449 528
0.86732 0.09875 510 1.9 455 521
0=i84893 0i08i46 400 2 457 512
0.82983 0.06756 320 2.1 457 503
0,.80988 0,05648 260 2,2 453 492
0.78956 0.04717 210 2.3 448 481
0.76_813 0.,03962 1.70 2..4 440 469
0.74854 0,0330,5 !40 2.5 433 458
0.72785 0.02791 120 2.6 424 445
O.7076 O.02323 99 2.7 415 433
0.68754 0.01977 83 2.8 405 421
0.6665 0.01636 70 2.9 395 408
O,6459 0.01369 59 3 384 395
0.62662 0.01152 50 3.1 373 383
0.60644 0.00977 42 3.2 362 370
0.5877 0.00833 36 3.3 351 359
0.56874 0:00708 31 3’4 30 347
0.55023 0.00594 27 3.5 329 335
0,.53238 0.00503 23 3.6 31.8 324
0.51497 0.00416 20 3.7 308 312
0.49761 0.00355 17 3.8 297 301
0.48094 0.00304 15 3.9 287 291
0.46465 0.0025 13 4 277 280
0.43288 0.00181 9.9 4.2 257 260
0.41804 00015’i 8.7 4"3 247 250
0."39064 O.O0109 6.8 4.5 230 233
0:37735 000091 6: 4.6 222 224
0.36425 0.00076 5.3 4.7 213 216
035147 0:0:0065 4.7 4.8 205 207
0.33945 0.00055 4.2 4.9 198 200
0’32752 6-’00048 37 5 I90 i92
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Net Benefit Net Benefit
Detection Risk Per Case Per Case
Rate False Positive 1:/ MOM Amniocentesis Ultrasound
0.98388 0.49958 12500 1 123 194
0.97669 0.42253 8900 1.1 -61 207
0.96792 0.35612 6500 1.2 -8 218
0.95746 0.29914 4800 1.3 37 227
0.94592 0.24988 3600 1.4 74 234
0.9323 0.2078 2700 1.5 105 238
0.91756 0.17187 2100 1.6 131 241
0.90148 O. 14301 1600 ii-7- i50 242
0.88461 O. 11906 1300 1.8 164 241
0.86732 0.09875 1000 1.9 176 240
0.84893 0.08i46 810 2 184 238
0.82983 0.06756 650 2.1 190 234
0.80988 0.05648 520 2.2 193 230
0.78956 0.04717 430 2.3 194 226
0.76813 0.03962 350 2.4 194 220
0.:78.54 0.0305 290 2.5 ! 93 2.15
0.72785 0.02791 240 2.6 190 210
0..7076 0,.02323 200 2.7 188 204
0.68754 0.01977 170 2.8 184 198
0.6665 0.01636 140 2.9 180 192
016459 01’0i’369 120 3 176 186
0.62662 0.01152 100 3.. 1 172 180
0.60644 0100977 85 3.2 167 174
O.5877 O.00833 72 3.3 162 168
0.56874 0.00708 62 3..4 157 163
O.55023 O.00594 53 3.5 152 157
-0153238 000503 46 316-’ 147 151
0’51497 0i00416 40 3.7 142 146
0.49761 0.00355 34 3..8 137 140
0.48094 0.00304 30 3.9 132 135
0.44856 0.00204 23 4.1 122 125
0.43288 0.00181 20 4.2 118 120
’0.-4i"804 0.00151 17 4.3 113 115
0.40434 0.00128 15 44 !09 1.! 1O’39064 O.O0109 14 4.5 105 106
0.37735 0.00091 12 4.6 101 102
0.36425 0.00076 11 4.7 96 98
0.35147 0.00065 9.4 4.8 92 94
0.33945 0.00055 8.3 4.9 89 90
0.32752 0.00048 7.4 5 85 86
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Incidencei/|200 70%_UPtake Rate
Net Benefit Net Benefit
Detection Risk Per Case Per Case
Rate False Positive 1:/ MOM Amniocentesis Ultrasound
0.98388 0.49958 15000 1 ’187 130
0.96792 0.35612 7800 1.2 -70 156
0.95746 0.29914 5800 1.3 -25 165
0,992 0:2,,,,9,8 ,00 :,,,. ?"2
0:9.2i i-.. 0,207, 00 .:,5 ,,,, .. -?,,8,
0.90148 0.14301 2000 1.7 92 183
O.88461 O. 11906 1500 1.8 107 184
0.86732 0.09875 1200 1.9 120 184
-0.84893 0.08146 970 2 130 183
0.80988 0.05648 630 2.2 141 178
0.78956 0.04717 510 2.3 143 175
0.76813 0.03962 420 2.4 144 171
0.74854 0.03305 350 2.5 145 !67
0.72785 0.02791 290 2.6 144 163
-017o73 01o2323 20 2.7 2 5
0.68754 0.01977 200 2.8 140 154
0.6665 0.01636 i70 2:9 138 149
O.62662 O.01152 120 3,, 1 131 140
0.60644 0.00977 100 3.2 128 135
0.56874 0.00708 74 3.4 120 126
0._55023 0,00594 64.,. 3.5 !.16 1.21
O.53238 O.0.0503 55_ 3;6 11,3 11.7
0.51497 0.00416 48 3.7 109 112
0.49761 O.O0355 ’1 3:8 i05 i08
0.48094 0.00304 36 3.9 101 104
0.46465 0.0025 31 4 97 100
0.44856 O.00204 27 4.1 94 96
0.41804 0.00151 21 4.3 86 88
0.40434 0:00i28 i8 4:4 8’3 84
0..39064 0;001.09 16 4.5 8,0 8.1
0.37735 0.00091 14 4.6 76 78
0.36425 0.00076 13 4.7 73 74
0.35!,. 0.00065 1 4.8 70 7.
0.33945 0.00055 10 4.9 67 68
0:272i.. :....i. 0,.000,,,8...I-..,8,:9, ".. ..;i 6... ......L............ 6 ..-. ...
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Incidencel/i500 70%Uptake Rate
Ht Bnfit Nt Bnfit
Detection Risk Per Case Per Case
Rate False Positive 1:/ MOM Amniocentesis Ultrasound
0.98388 0.49958 18800 1 -228 88
0.97669 0.42253 13400 1.1 -164 103
0.96792 0.35612 9700 1.2 -111 115
0.95746 0.29914 7200 1.3 -65 125
0.94592 0.24988 5400 1.4 -26 133
0.9323 0.2078 4100 1.5 6 139
0"91756 O. 17187 31O0 6 3 ]43
0.90148 O. 14301 2400 1.7 54 145
0.88461 0.11906 1900 1.8 71 147
0.86732 0.09875 1500 1.9 84 147
0.82983 0.06756 970 2.1 102 146
0.80988 0.05648 790 2.2 107 144
0.78956 0.04717 640 2.3 110 141
.0.76_8.13 0,.0.3962 520 2,4 ]. !.2 !:38
O.74854 O.03305 430 2.5 113 135
072785 0,02791 360 216 113 t 32
O.7076 O.02323 300 2.7 113 129
0.68754 0.01977 250 2.8 111 125
0,6665 0.0i-636 210 29 110 12i
0.6459 0.01369 180 3 108 117
O.62662 O.01152 150 3.1 105 113
0.60644 0.00977 130 3.2 102 109
0.5877 0.00833 110 3.3 100 106
0.55023 0.00594 80 3.5 93 98
0.53238 0.00503 69 3.6 90 94
0-51497 0:054’i-6 59 3:7 87 91
0.49761 0.00355 51 3.8 84 87
0.48094 0.00304 45 3.9 81 84
0.46465 0.0025 39 4 78 80
0.44856 0.00204 34. 4,.1 75 770.:43288 0.00181 30 4.2 72 73
0.41804 0.00151 26 4.3 69 70
0.40434 0.00128 23 4.4 66 67
0.39064 0.,001.09 20 4:5 63 64
0.37735 0.00091 18 4.6 60 62
0"36425 0.00076 6 4.-7 58 59
0.35147 0’00065 14 4.8 55 56
0.33945 0.00055 13 4.9 53 53
O.32752 O.00048 11 5 50 51
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Net Benefit Net Benefit
Detection Risk Per Case Per Case
Rate False Positive 1:1 MOM Amniocentesis Ultrasound
0.98388 0.49958 25000 1 -281 34
0.97669 0.42253 17900 1.1 -218 49
0.96792 0.35612 13000 1.2 -163 62
O’9546 0i299:i4 9600 i ]3 117 72
0.94592 0.24988 7200 1.4 -78 81
O.9323 0.2078 5500 1.5 -45 87
0191756 0.17187 400 116 ’17 92
O.88461 O. 11906 2600 i 18 22 98
0.86732 0.09875 2000 1.9 36 100
0"84893 O.08146 1600 2 48 i00
0.82983 0.06756 1300 2.1 57 100
O.80988 O.05648 1000 2.2 63 99
0.78956 0.04717 850 2,,3 67 98
O.76813 O.03962 700 2.4 70 96
0.74854 0.03305 580 2.5 73 94
0.72785 0.02791 480 2.6 74 92
0.7076 0.02323 400 2.7 74 90
0.68754 0.01977 330 2.8 74 87
0;66.5 O, 016.3.6 280 2,9 73 84
0:6459 0.01.369 240 3 72 82
0.62662 0.01152 200 3.1 7! 79
0.60644.. 0.,.0..0.977.. .170 _ .3,2 69 76
0.5877 0,.00833 140 3.3 67 73
0.56874 0.00708 120 3.4 65 71
0’55023 0100594 110 315 63 68
0.53238 0.00503 92 3.6 61 65
0.51497 0.00416 79 3.7 59 62
0.49761 0.00355 69 3.8 57 60
0.48094 0.00304 60 3..9 55 57
-i.’,0:464_65.. ’;; ..___ 0..0025 . .. 52 .-’4/....i., f ...,i... 5’3"..."’_".’.."/"i..’_’[’, ,lllll’l’ll,ll,r’’’l "--=,55,
0.44856 0.00204 45 4.1 50 52
0....43288 0.00.!,8.1 40. 4.,2 4.8 50
0.41804 0.00151 35 4.3 46 47
0.00i2s 3"=
0.39064 0.00109 27 4.5 42 43
0.37735 0.00091 24 4.6 40 41
0.36425 0.00076 21 4.7 38 39
0.35147 0.00065 19 4.8 36 37
0.33945 0.00055 17 4,.9 34 35
0.32752 0.00048 15 5 32 33
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Incidence.. 1/2174 70% Uptake,Rate
Net Benefit Net Benefit
Detection Risk Per Case Per Case
Rate Falsep,ositive 1:/, M0M Amniocentesis.,, Ultrasound
0;984 0;5 27200 1 -298
0.97669 0.42253 19400 1.1 -234 34
0.96792 0.35612 14100 1.2 -179 46
0.95746 0.29914 10400 1..3 -133 57
O,94592 0.24988 7800 1 ..4 -93 65
0.932 0.208 5900 1.5 -60 72
0.918 0i:i73 4600 16 ’32 77
0.902 0.143 3500 1,7 -10 81
. i_. o .......................................
0.867 0.099 2200 1.9 22 85
0.83 0.068 1400 2,. 1 43 87
0181 0’.0’57 i"i’06 2:2 49 86
0.79 0.05 930 2.3 52 85
0..77 0,0.4_... 760 2,4 58 84
0.749 0.033 620 2.5 61 82
0,729 0.028 520 2.6 62 80
0.708 0.023 430 2.7 63 78
0_.688 0.019 360 2.8 64 76
0.667 " 01016 300 2,9 63
0.647 0.014 260 3 62 71
0,628 0;.0,!2 220 3.1 61 69
0,,608 0.0097 180 3.2 60 67
0.589 0.0083 160 3.3 58 64
0.57 0.007 130 3.4 57 62
0.55 0.006 120 3.5 55 59
0.534 0.005 100 3.6 53 57
0.516 0.004 86 3.7 51 54
0.499 0.004 75 3.8 49 52
0.482 0.003 65 3.9 47 50
0.466 0.002 57 4 46 47
0.449 0.002 49 4.1 43 45
0.433 0.002 43 4.2 41 43
0.418 0.002 38 4.3 39 41
0.404 0.001 33 4.4 37 39
01391 01001 29 4-.5 36
0’377 O.O01 26 4.6 34 35
0.364 0.001 23 4.7 32 33
0.351 0.001 20 4.8 30 31
01"339 O01 i8 4:9 29
0.328 0.0006 16 5 27 28
44
:incidenfe .1125.00... _, ,7,,,0% Uptake_Rate
Net Benefit Net Benefit
Detection Risk Per Case Per Case
Rate False Positive 1:/ MOM Amniocentesis Ultrasound
0.98388 0.49958 31300" 1 ’3i3 2
0.97669 0.42253 22300 1.1 -249 18
0.96792 0.35612 16200 1.2 -195 31
0.95746 0.29914 12000 1.3 -148 41
0.94592 0.24988 9000 1.4 -108 50
0.9323 0.2078 6800 1.5 -75 57
0.91756 O. 17187 5200 1.6 -46 63
0.90148 0.14301 4100 t.7 -24 67
0.88461 0.11906 3200 1.8 -6 70
0.86732 0.09875 2500 1.9 9 72
01’84893 0"i")81’46 2000 2 21 73
0.82983 0.06756 1600 2.1 30 73
0 80988 0.05648 1300 2.2 37 73
0.78956 0..04717 1100 2.3 42 72
0.76813 0.03962 870 2,.4 45 71
O.74854 O.03305 720 2.5 48 70
0.72785 0.02791 600 2.6 50 68
0.7076 0.02323 500 2.7 51 67
0.68754 0.01977 410 2.8 52 65
0.6665 001.636 350 2.9 52 63
0.6459 0.01369 290 3 52 61
0160644 0.00977 210 3.2 i.....50
015877 0.’00833 180 3,3 49
0.56874 0.00708 150 3.4 47 52
O.55023 O.00594 130 3.5 46 50
0.53238 0,.00503 110 3.6 44 48
0.5.1497 0:00416 .,.9..9 3.7 43
0.49761 0.00355 86 3.8 41 44
0.48094 0.00304 75 3.9 39 42
0.46465 0.0025 65 4 38 40
0.44856 0.00204 57 4.1 36 38
0.43288 0,00181 5’6 4.2 34 36
0.41804 0.00151 44 4.3 32 34
0.40434 0.00128 38 4..4 31 32
0.39064 0.00109 34 4.5 29 30
0.37735 0.00091 30 4.6 28 29
0.36425 0.00076 26 4.7 26 27
0135147 0’00065 23 4.8 25
0.-33945 0.00055 21 4.9 23 24
0.32752 01’00048 i9 5 22 22
45
Net Benefit Net Benefit
Detection Risk Per Case Per Case
Rate False Positive 1:1 MOM Amniocentesis Ultrasound
0.98388 0.49958 37500 1 -345 -29
0.97669 0.42253 26800 1.1 -281 -14
0.,9692 0.356.!2 ,, !,9500 1:.2 -226 -1
0.95746 0.29914 14400 1.3 -179 10
0.94592 0.24988 10800 1.4 -139 19
0.9323 0.2078 8200 1.5 -105 27
0.91756 O. 17187 6300 1.6 -76 33
0.90148 0.14301 4900 1.7 -53 38
0.88461 O. 11906 3800 1.8 -35 41
0.86732 0.09875 3000 1.9 -19 43
0.82983 0.06756 1900 2.1 3 46
0.80988 0.05648 1600 2.2 11 47
0.78956 0.04717 1300 2.3 17 47
O.76813 O.03962 t 000 2.4 21 46
0.74854 0.03305 860 2.5 24 46
0172785 0102791 710 2,6 27
0.7076 0,0’2323 9’0 2.7 29 44
0.68754 0.01977 500 2.8 30 43
0.6665 0.01636 420 2.9 31 41
0.6459 0.01369 350 3 31 40
0.62662 0.01152 300 3.1 31 38
0.60644 0,00977 250 312 30 37
0.5877 0.00833 220 3.3 30 35
O.55023 O.00594 160 3..5 280.53238 0.00503 1-40- 3.6 27 31
0.51497 0.00416 120 3.7 26 29
0.49761 0.00355 100 3.8 25 28
0.48094 0.00304 90 3.9 24 26
0.46465 0.0025 78 4 23 25
0.4485-6 0100204 68 4’1 22 23
0.43288 0.00181 60 4.2 20 22
0.41804 0.00151 52 4.3 19 20
0.40434 0.00128 46 4.4 18 19
0:39064 000!.09., .i.;.i’1 .i-..i ..4:5. .i i7 . ...ii.........i.’ ,i 18, ..
0.37735 0.00091 36 4.6 16 16
0.36425 0.00076 32 4.7 14 15
0.35147 0.00065 28 4.8 13 14
0.33945 0.00055 25 4.9 12 13
0,3275 0.00048 22 5 i1 i2
Appendix
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Net Benefit Net Benefit
Detection Risk Per Case Per Case
Rate False Positive t :/ MOM Amniocentesis Ultrasound
0.98388 0.49958 6300 1 223 588
0.97669 0.42253 4500 1.1 292 601
0.96792 0.35612 3200 1.2 349 611
O.95746 0.29914 2400 11-3 396 617
0.94592 0.24988 1800 1.4 435 620
0.9323 0.2078 1400 1.5 465 620
0.91756 0’17187 1000 ii 489 618
0.90148 0.14301 820 1.7 505 613
0.88461 0111906 640 1i8 516 606
0’86732 0.09175 510 i i.9 522 598
O.84893 O.08146 400 2 525 588
0.82983 0.06756 320 2’1 525 578
0.80988 00568 260 22 521 -: 566
0.78956 0.04717 210 2.3 515 553
O.76813 O.03962 170 2.4 506 539
0.74854 0.03305 140 2.5 498 526
01-72785 0.02791 120 2’6 488 512
017076 0102323 99 2.7 47a 498
O.68754 O.01977 83 2’8 466- 484
0.6665 0.01636 70 2.9 454 469
0.6459 0.01369 59 3 441 455
0.62662 0.0ii52 50 3.1 429 441
0’60644 010097 4 3’2 416 426
0.5877 0.00833 36 3.3 404 413
0.56874 0.00708 31 3.4 391 399
O.55023 O.00594 27 3.5 378 386
0.53238 0.00503 23 3.6 366 373
0.51497 0,016 2:0 3. 354 360
.",,,,0.49761 ’.;/i"’’". ,o.O0355, ’,,-’,,/,,i"Ti’i.""’i ,.3:8 [; 342 -. 347..
0.48094 0.00304 15 3.9 330 335
0;.46465 0,0.025 !..3 4 319 32.3
0.44856 0.00204 11 4.1 308 311
0.43288 0.00181 9.9 4.2 296 300
0.41804 0.00151 8.7 4.3 286 289
0.40434 0.00128 7.7 4.4 276 279
O.39064 O.O0109 6.8 4.5 266 269
0..37735 0.00091 6 4,6 256 259
0.36425 0,.00076 5.3 4:7 247 249
0.35147 0.00065 4.7 4.8 238 240
Q.3.3945 0.00055 4.2 4..9 229 231
0.32752 0.00048 3.7 5 220 222
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Net Benefit Net Benefit
Detection Risk Per Case Per Case
Rate False Positive 1:/ IViOM Amniocentesis Ultrasound
0.98388 0.49958 12500 1 -138 224
0.97669 0.42253 8900 1.1 -67 240
0.96792 0.35612 6500 1.2 -6 253
0.95746 0129914 4800 113 45 262
0.,94592 0,24988 3600 1.4 88 270
0.9323 0.2078 2700 1.5 123
...................... 275
0.91756 0117187 2100 1 16 152 278
0.90148 0.14301 1600 1.7 174 279
0.86732 0.09875 1000 1.9 204 277
0,8489.3 0.08.146 8.10 2 21.4 274
0.82983 0.06756 650 2.1 220 271
0.80988 O.05648 520 2.2 223 266
O78956 O.04717 436 2.3 225 261
0.76813 0.03962 350 2.4 224 255
O.74854 O.03305 290 2.5 223 249
0.72785 0:0279! .240 2,6 221 243
0.7076 0.02323 200 2.7 218 236
0.68754 0.01977 170 2.8 214 230
0.6665 0.01636 140 2.9 209 223
O.62662 O.01152 1O0 3.1 199 209
O.60644 0"00977 85 32 193 202
0.5877 0.00833 72 3.3 188 195
0.56874 0.00708 62 3.4 182 189
0,55023_ ; 0.00594 .." ;_. 53". _. 3;5’.... ...." ...... 176. ,’.".. -..-;;...182
0.53238 0.00503 46 3.6 171 176
0.5497 5:004i6 ’40 37 i65 169
0.49761 O.00355 ’4 3.8 159 163
0,809 0:0030 30 3,9 5 157
0.665 00025 26 8 !5
0.44856 0.00204 23 4.1 143 145
O]43288 0"00181 20 4.2 137 140
0.41804 0.00151 17 4.3 132 134
0.40434 0.00128 15 4.4 127 129
0.39064 0.00109 14 4.5 122 124
0.37735 000091 12 46 118 119
0.36425 0.00076 11 4.7 113 115
0.35147 0.00065 9.4 4.8 108 110
-.
0.32752 0.00048 7.4 5 100 101
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Incidencel/12
,80% Uptake RateNetBenefit Net:Benefit
Detection Risk Per Case Per Case
Rate False Positive 1:/ MOM Amniocentesis Ultrasound
0.98388 0.49958 15000 1 -210 151
0.97669 0.42253 10700 1.1 -138 168
096792 O.356:!2 7800 !.2 .,."77 18.1
0.95746 0.29914 5800 1.3 -26 192
0.94592 0.24988 4300 1,. 18 200
0.9323 0,.2078 3300 1,5 55 206
0.91756 O. 17187 2500 1.6 85 210
0.90148 O. 14301 2000 1.7 108 212
0’88461 0’"11906 1500 118 i26 213
0,86732 0.09_875 1200 1=9 140 21.3
0.84893 0.08146 970 2 151 212
0.82983 0.06756 780 2.1 159 209
0.80988 0.05648 630 2.2 164 206
0.78956 0.04717 510 2.3 167 202
0,,76813 0;03962 ..420 2:..4 168... 198
0.74854 0.03305 350 2-5 168 194
0.72785 0.02791 290 2.6 167 189
0.7076 0.02323 240 2.7 166 184
0.687’54 010’i-’7’7 2’00 2.8 163 179
0.6665 0.01636 170 2.9 160 173
0.6459 0.01369 140 3 157 168
O.62662 O.01152 1.20 3..1 163
0.60644 0.00977 100 3.2 149 157
0,5877 0.00833 87 3.3 145 152
0.56874 0:00708 4 3,4 i40 i47
0.55023 0.00594 64 3.5 136 141
0.53238 0.00503 55 3.6 132 136
0.51497 0.00416 48 3.7 127 131
0.49761 0.00355 41 3.8 123 126
0,48094 0.00304 36 3.9 118 122
0.46465 0.0025 31 4 114 117
0.44856 0.00204 27 4.1 110 112
0.41804 0.00151 21 4.3 101 103
0.40434 0.00128 18 4.4 98 99
0,.39064 0.00.109 1...6 4.5 94 95
0.37735 0.00091 14 4.6 90 91
0’36425 0.00076 13 4"7 86 88
O.33945 O.00055 0 4.9 79 80
0.32752 0.00048 8.9 5 76 77
5O
Net Benefit Net Benefit
Detection Risk Per Case Per Case
Rate False Positive 1:/ MOM Amniocentesis Ultrasound
019838 , 0.49958 18800 i 257 104
0.97669 0.42253 13400 1.1 -185 121
0.96792 0.35612 9700 1.2 -124 134
0.95746 0.29914 7200 1.3 -71 146
0.94.59.2 0,24988 540.0 1.,4
-27.. 154
0.9323 0.2078 4100 1.5 10 161
0.91756 O. 17"i87 3100 i".6 41 166
0.90148 0.14301 2400 1.7 65 169
0.8846i 0’. 1’1906 1900 i’."8 83 171
0:86732 0109875 1500 i:9 9’9 171
O.84893 O.08146 1200 2 111 171
0.82983 0.06756 970 2.1 119 169
0.’898’8 0.05648 9’0 2.2 125 167
0.78956 0.04717 640 2.3 129 164
0:768! 3 0.03962 520 2A 131 161
O.74854 O.03305 430 2.5 132 158
0.72785 0.02791 360 2.6 132 154
O.7076 O.02323 300 2.7 132 150
0.68754 0.01977 250 2.8 130 1.46
0.6665 0.01636 210 2.9 128 141
0.6459 0.01369 180 3 126 137
0.62662 0.01152 150 3.1 123 133
0=60644 0.00977 130 3.2 120 128
0..5877 000833 1!:0 , 33 1.1.7 124
0,56874 000708 93 3.4 113 119
O.55023 O.00594 80 3.5 110 115
0.53238 0.00503 69 3.6 106 111
0,49761 0.00355 51 3,8 99 102
0,48094 0.00304 45 3.9 95 98
0.4.65_ 0..0025 39 4 92 95
0.44856 0,00204 4.1 88 91
0.43286 0.00181 30" 4.2 85 7
0,41804 0.00151 26 4.3 81 83
0.40434 000i28 -23 4’4 78 80
0,39064 0’00109 20 4"5...........................75 77
0.37735 0.00091 18 4,6 72 73
0,36425 0.00076 16 4,7 69 70
035..47 0,00065 !.4 48. 66 67
0.33945 0.00055 13 4.9 63 64
0;2752 .’-._. 0.00048. 11 ."5 ,.,,, ,, 60 . ,,,,,,
5]
Net Benefit Net Benefit
Detection Risk Per Case Per Case
Rate False Positive 1:/ MOM Amniocentesis Ultrasound
0.98388 0.49958 25000 1 -319 42
0.97669 0.42253 17900 1.1 -246 59
0’96792 0.3561. 13000 1.2 ’184 74
0.;.95746 0.29.91.4 9600 1..;..3 -131 85
0.94592 0.24988 7’200 1.4 -86 95
0.9323 0.2078 5500 1.5 -48 103
0.91756 0.17187 4200 1.6 -16 108
0.90!48 O. 14301 3300 1.7 8 112
0.88461 O. 11906 2600 1.8 28 115
O’86732 0 09875 2000 1.9 45 .11 7_.. ...
0.84893 0.08146 1600 2 58 117
0.82983 0.06756 1300 2.1 68 117
0.80988 0.05648 000 2,:2 75 1.!6
0.78956 0.04717 850 2.3 80 115
0..76813 0.,.03962 .700 2.4 83 !13
O.74854 O.03305 580 2.5 86 111
0,72785 0’.02791 ’’’0 ’.6 87 108
0,68754 0,01977 330 2,8 87 102
0,6665 0,01636 280 2,9 87 99
06459 0’01369 240 3 85 96
0’62662 0[01152 200 3,1 84 93
0,60644 0,00977 170 3,2 82 90
_. 0,5877’.’.’."’...’""..’"’000833 140 3,3 80 . 87
0,56874 0,00708 120 34 78 83
0,55023 0,00594 110 3,5 75 80
0,53238 0,00503 92 3,6 73 77
051497 0,00416 7 3,7 7 74
0,48094 0,00304 60 3,9 65 68
0’46465 0"0025 52 4 63 65
0,44856 000204 45 4,1 60 62
0,43288 0,00181 40 4,2 58 60
0,41804 0,00151 35 4,3 55 57
0,40434 000i28 31 4’4 53 54
0,39064 O00’109 27 45 f 51 52
0.37735 0.00091 24 4.6 48 50
0.36425 0.00076 21 4.7 46 47
0.35147 0.00065 19 4.8 44 45
0:33945 0.’00055 17 4.9 42 43
0.32752 0.00048 15 5 40 40
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Net Benefit Net Benefit
Detection Risk Per Case Per Case
Rate False Positive 1:i MOM Amniocentesis Ultrasound
0.984 0.5 27200 1 -337 24
0.97669 0.42253 19400 1.1 -264 41
0.96792 0.35612 14100 1.2 -202 56
0.95746 0.29914 10400 1.3 -149 68
0.94592 0,24988 7800 1.4 -103 77
0.932 0.208 5900 1.5 -66 85
0.918 0"’i73 46(0 1’16 34 91
0.902 0.143 3500 1.7 -8 96
0.885 O. 119 2800 1.8 12 99
0.867 0.099 2200 1.9 28 101
01849 0.082 1800 2 42 102
0.83 0.068 1400 2.1 52 102
0.81 0.057 1100 2.2 59 101
0.79 0,05 930 2,3 63 99
0.77 0.04 760 2.4 69 99
0.749 0.033 620 2.5 72 97
0.729 0.028 520 2.6 74 95
0..708 0.023 430 2,7 75
0.688 0.019 360 2.8 75 90
0.667 0.016 300 2.9 75 87
0.647 0.014 260 3 74 84
0.628 0.012 220 3.1 72 82
0’608 0,’0097 180 3,2 7i
0.589 0.0083 160 3.3 69 76
0.57 0.007 130 3.4 67 73
0.55 01006 120 3.5 65
0.534 0.005 100 3.6 63 68
0.516 0,004 86 3.7 61 65
0.499 0.004 75 3.8 59 62
0.482 0.003 65 3.9 57 60
01466 0002 57 4 55 57
0.449 ...0.:002 4.9 4:1 52
0.433 0.002 43 4.2 50 52
0.418 0.002 38 4.3 48 49
0.404 0.001 33 4.4 46 47
0.391 0.001 29 4.5 44 45
0.377 0.001 26 4.6 41 43
0.364 0.001 23 4.7 39 40
0.351 0.001 20 4.8 37 38
0.339 0.001 18 4.9 36 36
0.328 0.0006 16 5 34 34
Net Benefit Net Benefit
Detection False-
Rate Positive
0.98388 0.49958
0.97669 0.42253
Risk Per Case Per Case
1:1 MOM Amniocentesis Ultrasound
31300 1 -355 -6
22300 1.1 -282 23
0.96792 0.35612 16200 1.2 -220 38
0.95746 0,29914 12000 1.3 -166 50
0.94592 0.24988 9000 1.4 -121 60
O.9323 0.2078 6800 1.5 -82 68
0.91756 0.17187 5200 1.6 -50 75
0.88461 0.11906 3200 1.8 -4 82
O.84893 O.08146 2000 2 27 86
0.82983 0.06756 1600 2.1 37 87
0.80988 0.05648 1300 2.2 45 86
0.78956 0.04717 1100 2.3 51 85
0.76813 0.03962 870 2.4 55 84
O.74854 O.03305 720 2.5 58 83
0.72785 0.02791 600 2.6 60 81
0.7076 0.02323 500 2.7 62 79
0:’8754 0’5’i977 410 2’8
0.6459 0.01369 290 3 62 72
0,6266.2..,....,"-; ...i52; ’._.. ’250..
0.6644 0009_77 21:0 3.2 60 67
0.5877 0.00833 180 3.3 58 65
0.53238 0.00503 110 3.6 53 58
0.51497 0.00416 99 3.7 52 55
0’-9761 0:00355 86 38 50 53
0.48094 0.00304 75 3.9 48 50
0.46465 0.0025 65 4 46 48
0.44856 0.00204 57 4.1 44 46
043288 0.00181 ’0 4’2 42
0.41804 0.00151 44 4.3 40 41
0.40434 0.00128 38 4.4 38 40
0.39064 0.00109 34 4.5 36 38
0.37735 0.00091 30 4.6 35 36
0,36425 0.00076 26 4.7 33 34
0.35147 0.00065 23 4.8 31 32
0.33945 0.00055 21 4.9 29 30
0,32752 0.00048 19 5 28 28
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Net Benefit Net Benefit
Detection Risk Per Case Per Case
Rate False Positive 1:/ MOM Amniocentesis Ultrasound
0.98388 0.49958 37500 1 -391 -31
O.97669 0.42.2.53 268.0.0 1.. ! ,318 -1301962 0.35612 19500 1.2 -255 2
0.95746 0.29914 14400 1..3 -202 14
0’4592 0124988 10800 :i""i4 :156 25
0.9323 0.2078 8200 1.5 -117 34
0.91756 0.17187 6300 1.6 -84 41
0.90148 O. 14301 4900 1.7 -58 46
0.88461 O. 11906 3800 1.8 -37 50
0.86?32 --5 3000 1::9 Ll 9 53
0.84893 o o8i46 2400 2 -5 55
0,82983 0.06756 1900 2.1 7 56
.-. 0809.8.8 0.0564_8 1600.. Z2 15 56
0.78956 0.04717 1300 2.3 22 56
0.76813 0._03962 1000 2.4 27 56
0.74854 0.03305 860 2.5 31 55
0.72785 0.02791 710 2.6 33 54
0.7076 0.02323 590 2.7 36 53
0,68754 0.01977 500 2.8 37 52
0.6665 0.01636 420 2.9 38 50
0.6459 0,01369 350 3 38
0,62662 0.01152 300 3.1 38 47
0.60644 0.00977 250 3.2 37 45
0.56874 0.00708 190 3.4 36 41
O.55023 O,00594 160 3.5 35 40
0.53238 0.00503 140 3.6 34 38
0:51497 0,004i6:- 10 3:7 33 36
0.49761 0.00355 100 3.8 31 34
0.48094 0.00304 90 3.9 30 33
0.46465 0.0025 78 4 29 31
O.44856 O.00204 68 4.1 27 _.., 29
0.41804 0.00151 52 4.3 25 26
0,40434 0.00128 46 4,4 23 25
0.39064 0,00109 41 4,5 22 23
0.37735 0,00091 36 4.6 21 22
0.36425 0.00076 32 4.7 19 20
0.3547 000065 28 48 18 19
0.33945 0,00055 25 4.9 17 18
0,32752 0.00048 22 5 16 16
Appendix 6
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Net Benefit Net Benefit
Detection Risk Per Case Per Case
Rate False Positive 1:! MOM Amniocentesis Ultrasound
ii,.19; .i ii:_ 0:,90’ /:_ 600.. i,._
’
’i... 6: ".....-=. . . . 6
0.97669 0.42253 4500 1.1 214 446
0.96792 0,35612 3200 1.2 257 453
0.95746 0.29914 2400 1.3 292 457
0.94592 029,88 !,80 1.A 321 .460
.0,9323 0:2078 140,0 1.5 344 4.6.0
0.91756 0::1,71_87 1000 1:,, 362 458
0.90148 0.14301 820 1.7 374 454
O.88461 O, 11906 640 1.8 382 449
0.86732 0.09875 510 1.9 387 443
0.84893 0.08146 400 2 389 436
0.82983 0.06756 320 2.1 389 428
0.80988 0.05648 260 2.2 386 419
0.78956 0.04717 210 2.3 381 410
0,768.1,3 0.039,62 1.70 .2,4 375 399
0.74854 0.03305 140 2.5 369 389
0.72785 0,02791 120 2.6 361 379
0.7076 0.02323 99 2.7 353 368
0,68754 0,,.01977 83 2.8 345 358
0.6665 0.01636 70 2.9 335 347
0.6459 0.01369 59 3 326 336
0.62662 0.01152 50 3.1 317 326
0.60644 0.00977 42 3,2 307 315
0’5877 0.00’833 6 3’3 298 305
0.56874 0.00708 31 3.4 2’88 294
O.55023 O,00594 27 3.5 279 284
O.53238 O.00503 23 3,6 270 274
0.51497 0.00416 20 3.7 261 265
0.49761 0,00355 17 3.8 252 255
0.48094 0.00304 15 3.9 243 246
0’46465 0’.0025 i3 4 234 237
0.44856 O.00204 11 4.1 226 228
0.43288 0.00181 9.9 4.2 217 220
0.41804 0.00151 8.7 4.3 209 212
0.40434 0.00128 7,7 4.4 202 204
0.39064 0.00109 6"8 4’5 194 197
0.37735 0,00091 6 4.6 187 189
0.36425 0.00076 5.3 4.7 180 182
0.35147 0.00065 4,7 48 173 175
0,33945 0.00055 4.2 4.9 167 168
0.32752 0.00048 3.7 5 160 162
57
Incidence 1/I000 60% Uptake Rate
Net Benefit Net Benefit
Detection Risk Per Case Per Case
Rate False Positive 1:/ MOM Amniocentesis Ultrasound
0.98388 0.49958 12500 1 -109 163
0.97669 0.42253 8900 1.1 -55 175
0.96792 0.35612 6500 1.2 -10 184
0.95746 0.29914 4800 1.3 28 192
0,94592 0;.24988 3600 1..4 61 !97
0.9323 0.2078 2700 1.5 87 201
0.91756 0.17187 2100 1.6 109 204
0.90148 O. 14301 1600 1 ..7 125 204
0.88461 O. 11906 1300 1.8 138 204
0.86732 0.09875 1000 1,9 148 203
’0.84893 008i46 810 2 155 201
0.82983 0.06756 650 2.1 160 198
0.80988 0.05648 520 2..2 162 194
0.78956 0.04"717 430 2.3 164 191
0.74854 0.03305 290 2.5 162 182
072785 0102791 240 216 i60 177
0,7076 0.02323 200 2.7 158 172
0.68754 0.01977 170 2.8 155 167
0.6665 0.01636 140 2.9 152 162
0.6459 0.01369 120 3 148 157
O.62662 O.01152 1 O0 3.1 144 152
0,60644 0:00977 85 .3.2 140 146
0.5877 0.00833 72 3..3 136 142
...
0,56874 0;.00708 62 3.4 132 136
0.55023 0.00594 53 3.5 127 132
0,53238 0,.00.503 46 3.6 1.23 127
0.51497 0.00416 40 3.7 119 122
0:49761 0:00355 "34 3.8 115 1:17
0.48094 0.00304 30 3.9 110 113
0.46465 0.0025 26 4 106 108
0.44856 O.00204 23 4.1 102 104
0.43288 0,.00!. 81 20 4.,.2...t 98 100
0.41804 0.00151 17 4.3 94 96
0.40434 0.00128 15 4.4 90 92
0.39064 0.00109 14 4.5 87 88
037735 010091 12 46 83 85
0.36425 0.00076 11 4.7 80 81
0.35147 0.00065 9.4 4.8 76 77
0.33945 0.00055 8.3 4.9 73 74
0:-3252 0:00’048 7,4 5 70 7i
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incidence,l/120o 60% Uptake Rate
Net Benefit Net Benefit
Detection Risk Per Case Per Case
Rate False Positive 1:/ MOM Amniocentesis Ultrasound
0.98388 0.49958 15000 1 -163 108
0.97669 0.42253 10700 1.1 -109 121
0.96792 0.35612 7800 1.2 -63 131
0.95746 0.29914 5800 .1._..3 ,24 139
0.94592 0.24988 4300 1.4 9 145
0.9323 0.2078 3300 1.5 36 150
0.91756 O. 17187 2500 1.6 59 153
0.90148 0.14301 2000 1.7 76 154
0.88461 O. 11906 1500 1.8 89 155
0.86732 0.09875 1200 1.9 100 155
0.84893 0.08146 970 2 108 154
0.82983 0.06756 780 2.1 114 152
0.80988 0105648 630 2.2 118 i50
0.78956 0.04717 510 2.3 120 147
0.76813 " 0.03’9’2 420 2’4 :12i 143
0.74854 0.03305 350 2.5 121 140
0.72785 0.02791 290 2.6 120 137
O.7076 O.02323 240 2.7 119 133
0.68754 0.01977 20’0 "i’ ";i17 1-29
0.6665 0.01636 170 2.9 115 125
0.6459 0.01369 140 3 112 121
0.62662 0.01152 i20 3.1 110 117
0.5877 0.00.83.3 87 3.,3 104 !09
0.56874 0.00708 74 3.4 100 105
-_.0-55023 0,.00594 64 3,5 97 !0,]
0,53238. 0.00503 55 3.6 94 97
0.51497 0.00416 48 3.7 90 94
0,49761 0,003.55 41 3.8 87 90
0.48094 0.00304 36 3.9 84 86
0.44856 0.00204 27 4.1 77 79
0.43288 0.00181 24 4.2 74 76
0.41804 0.00151 21 4.3 71 73
0.40434 0.00128 18 4.4 68 70
0.39064 0.00109 16 4.5 65 66
0.36425 0.00076 13 4.7 60 61
035147 0.00065 11 4.8 57 58
0.33945 000055 1’0 ".’9 54 55
0.32752 0.00048 8.9 5 52 53
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Net Benefit Net Benefit
Detection False- Risk
Rate Positive 1:/
0i, !i"_... ,o,i .. 0o.
0.97669 0.42253 13400
Per Case Per Case
MOM Amniocentesis Ultrasound
. ,.. :."i ... .. .’ 7.-"i
1.1 -144 86
0.96792 0.35612 9700 1.2 -98 96
0.95746 0.29914 7200 1.3 -59 104
i -.0,’’ i 0’.,’"...... ,.0o,’_.I,,I .ii....i.
0.9323 0.2078 4100 1.5 3 116
0.91756 0.17187 3100 1.6 26 120
0.90148 0.14301 2400 1.7 43 122
0.88461 0.11906 1900 1.8 58 123
0.86732 0.09875 1500 1.9 69 123
O.84893 O.08!46 1200 2 78 123
0.82983 0.06756 970 2.1 85 122
0.80988 :i i01056481 i, 71901 ."i.....:212 ii. .,89 12.0... ..
0.78956 0.04717 640 2.3 92 118
0.76813 0.03962 520 2.4 93 116
0.74854 0.03305 430 Z5 94 113
0.72785 0.02791 360 2.6 94 110
0.7076 0.02323 300 2.7 94 107
0.68754 0.01977 250 2.8 93 104
0.6665 0.01636 210 2.9 91 101
0.6459 0.01369 180 3 89 98
0.62662 0.01152 150 3.1 87 94
0.60644 0.00977 130 3.2 85 91
015877 0.00833 1:i0 3.3 12 88
0..56874 0.0.0.708 93.. 3.4 ....i. 80 ,..,.....-::.i .= :I:B-. . .._..
0.55023 0.00594 80 3.5 77 81
.0.53238 0..00503 6,9 3.6 75
0.51497 0.00416 59 3.7 72 75
0,49761 0100355 51 3’=8 69
0.48094 0.00304 45 3.9 67 69
0’46465 i’"ii 0.0025., .’ .,i".’i.’..." ..i’" "".’.’ "4".i.’.""i"_ ..’’_’
0.44856 0.00204 34 4.1 61 63
0,.432.88 0..._00181 30 4,2 59
0.41804 0.00151 26 4.3 56 57
0.40434 0.00128 23 4.4 54 55
0.39064 0.00109 20 4.5 51 52
0.37735 0.00091 18 4.6 49 50
0.36425 0.00076 16 4.7 47 48
’..0,35!.47 ...i":i.._ 0:.0006.5.... . 4-:8i"
0.33945 0.00055 13 4.9 42 43
0.32752 0.00048 11 5 40 41
Net Benefit Net Benefit Per
Detection Risk Per Case Case
Rte False P0s,!tive 1:/ MOM Amni0centesis Ultrasound
0.,.98388 0,.49958 25000 1 -244 27
0.97669 0.42253 i 7900 1.1 -190 39
0.96792 0.35612 13000 1.2 -143 50
0.95746 0.29914 9600 1.3 -103
0.94592 0.24988 7200 1.4 -70 66
0.9323 0.2078 5500 1.5 -41 72
0.91756 0.17187 4200 1.6 -17 76
0.90148 0.14301 3300 1.7 1 79
O.88461 O. 11906 2600 1.8 16 81
0.86732 0.09875 2000 1.9 28 83
0.84893 : 0i’8146 1600 2
0.82983 0.06756 1300 2.1 46 83
0.80988 0.05648 1000 2.2 51 82
O.78956 O.04717 850 2.3 55 81
0.76813 0.03962 700 2.4 57 79
0.74854 0.03305 580 2.5 59 78
0.72785 0.02791 480 2.6 60 76
0.7076 0.02323 400 2.7 61 74
0.68754 0.01977 330 2.8 60 72
016665 001636 285 2:g 60 70
0.6459 0.01369 240 3 59 67
0.60644 0.00977 170 3.2 56 62
0.5877 0.00833 140
0.56874 0.00708 120 3.4 53 58
0.55023 0.00594 110 3.5 52 55
0.53238 0.00503 92 3.6 50 53
0.51497 0.00416 79 3.7 48 51
0.49761 0.00355 69 3.8 46 48
0.48094 0’00;304 60 3, 44 46
0’-46465 0:0025 52 4
0.44856 0.00204 45 4.1 40 42
0.43288 0.00181 40 4.2 38 40
0.41804 0.00151 35 4..3 36 38
0.40434 0.00128 31 4.4 35 36
0.39064 0.00109 27 4.5 33 34
0.37735 0.00091 24 4.6 31 32
0.36425 0.00076 21 4.7 30 30
O.35147 O;000.65 19
0.33945 0.00055 17 4.9 26 27
0.32752 0.00048 15 5 25 25
61
Incidence i2i74 60%Uptake.Rate
Net Benefit Net Benefit
Detection Risk Per Case Per Case
Rate FalSe Positive 1:! MOM Amniocentesis Ultrasound
0.984 0.5 27200 1 -258 13
0.97669 0.42253 19400 1.1 -203 26
0.96792 0.35612 14100 1.2 -156 37
0.95746 0.29914 10400 1.3 -117 46
0.94592 0.24988 7800 1.4 -83 53
0.932 0.208 5900 1.5 :54 59
0.918 0.173 4600 1.6 -31 63
0.902 O. 143 3500 1.7 -11 67
0.885 O. 119 2800 1.8 4 69
0.867 0.099 2200 1.9 16 70
0.849 0.082 1800 2 26 71
0.83 0.068 1400 2.1 34 71
0.81 0.057 1100 2.2 39 71
0.79 0.05 930 2.3 42 70
0.77 0.04 760 2.4 47 69
0.749 0.033 620 2.5 49 68
0.729 0.028 520 2.6 50 66
0.708 0.023 430 2.7 51 64
0.688 0.019 360 2.8 52 62
0.667 0.016 300 2.9 51 60
0.647 0.014 260 3 50 58
O.628 O.012 220 3.1 49 56
0.608 0.0097 180 3.2 48 54
0.589 0.0083 160 3.3 47 52
0.57 0.007 130 3.4 46 50
O’55 01006 120 3:5 44
0"34 O.005 1 O0 3,6 43 46
0.516 0.004 86 3.7 41 44
0.499 0.004 75 3.8 39 42
0.482 0.003 65 3.9 38 40
0.466 0"002 57 4 36 38
0.449 0.002 49 4.1 34 36
0.433 0.002 43 4.2 32 34
0.418 0.002 38 4.3 31 32
0;404 O00.1 33 :,,4, 29 30
0.391 0.001 29 4.5 28 29
’i’ ...i ’.
0.364 0.001 23 4.7 25 25
0.351 0,001 20 4.8 23 24
0.339 0.001 18 4.9 22 22
0.328 0.0006 16 5 20 21
62
Incidence 1/2500 60% Uptake Rate
Detection False Positive Risk MOM Net Benefit Net Benefit
Rate 1:/ Per Case Per Case
Amniocentesis Ultrasound
0.98388 0.49958 31300 1 -271 -1
0.96792 0.35612 16200 1.2 -170 23
0.95746 0.29914 12000 1.3 -130 32
0.94592 0.24988 9000 1.4 -96 40
0.9323 0.2078 6800 1.5 -67 46
0.91756 0.17187 5200 1.6 -43 51
0.90148 O. 14301 4100 1.7 -24 54
0.88461 0.11906 3200 1.8 -8 57
0,8732 0.09875 250 i’9 4 58
084893 O’08i46 2000 2 i" 60
0.82983-);.;0:’06756 ’.. ......_1600 _[...-:.. 2:1’.".." _"’’.2a,."’’:’_"’__’."’ ’.
0.80988 0.05648 1300 2.2 29 60
0.78956 ., 0.04717 1,1,00 ..2.3 33 59
0.76813 0.03962 870 2,4 36 58, 720
0.72785 0.02791 600 2.6 40 56
0.7076 0.02323 500 2.7 41 54
0,68754 0 0.1977 53 .L
0.6665 0.01636 350 2.9 42 51
0,6459 0.01369 290 3 41 49
0.62662 0.01152 250 3.1 41 47
060644 0.00977 210 3’2 40 46
0.5877 0.00833 180 3.3 39 44
0.56874 0.00708 150 3.4 38 42
O.55023 O.00594 130 3.5 36 40
0.51497 0.00416 99 3.7 34 36
0.49761 0.00355 86 3.8 32 35
0.48094 0.00304 75 3.9 31 33
0.46465 0.0025 65 4 29 31
0.43288 0.00181 50 4.2 26 28
0.41804 0001.51 4 4..3 25 26
0.40434 0.00128 38 4.4 24 25
0.39064
.0.00109 34 4,5 2
0.37735 0.00091 30 4.6 21 22
0.325 0.00076 26 4.7 20 20
0.35147 0.00065 23 4.8 18 19
0.33945 0.00055 21 4.9 17 18
0"32752 0’00048 19 5 16
63
Detection False Risk MOM Net Benefit Net Benefit
Rate Positive 1 :/ Per Case Per Case
Amniocentesis Ultrasound
0.98388 0.49958 37500 1 ’298
0.97669 0.42253 26800 11 1 -243
0.96792 0.35612 19500 1.2 -196 -4
0’95746 029914 14400 113 ’i56 6
0.94592 0.24988 10800 t .4 -122 14
0.9323 0.2078 8200 1.5 -93 20
0.91756 6300 1, 6 :.66 25
0:90148 O. 14301 4900 1i-:7 :48
0.88461 0.11906 3800 1.8 -33 32
0.86732 0.09875 3000 1.9 -19 34
O.84893 O.08146 2400 2 -8 36
0.82983 0.06756 1900 2.1 0 37
0.80988 0.05648 1600 2.2 6 37
0.78956 0.04717 1300 2.3 11 37
0.76813 0.03962 1000 2.4 15 37
0:74854 0’03305 860 2"5 i8 36
0’72785 0.0279i 7i0 216 20 36
0.7076 0.02323 590 2.7 22 35
0’68754 0’01977 500 2’8 23 34
0.6665 0.01636 420 2.9 23 33
0:6459 O.01369 350 3 24 31
O.62662 O.01152 300 3.1 23 30
0160644 0100977 250 3.2 23 29
015877 0.00833 220 3’3 23
0.56874 0.00708 190 3.4 22 26
0.53238 0.00503 140 3.6 20 23
0.51497 0.00416 120 3.7 20 22
0.49761 0.00355 100 3.8 19 2i
0.48094 0.00304 90 3.9 18 19
0’46465 00025 8 4 17 18
0.44856 0.00204 68 4.1 16 17
0.43288 0.00181 60 4.2 14 16
0.41804 0.00151 52 4.3 13 t5
0.434 0.00128 46 4.4 12 13
0.39064 0.00109 41 4.5 11 12
0.37735 0.00091 36 4.6 11 11
0.36425 0.00076 32 4.7 10 10
0.35147 0.00065 28 4.8 9 9
0.33945 0.00055 25 4.9 8 8
0.32752 0.00048 22 5 7 7
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